← Expert Review of Precision Medicine and Drug Development
Papers in Expert Review of Precision Medicine and Drug Development
Page 1 · newest first
- Advances in functional radionuclide imaging and therapy for individualized management of patients: the growing importance of Nuclear Theranostics in Precision Oncology PracticeExpert Review of Precision Medicine and Drug Development · 2025
- Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestationsExpert Review of Precision Medicine and Drug Development · 2025
- Immunotherapy for precision medicine in colorectal cancerExpert Review of Precision Medicine and Drug Development · 2025
- Challenges and opportunities for precision medicine in developing nationsExpert Review of Precision Medicine and Drug Development · 2025
- Drug discovery in the context of precision medicine and artificial intelligenceExpert Review of Precision Medicine and Drug Development · 2024
- Precision Medicine Paradigms in Allergic Rhinitis: Navigating Immunotherapy and Digital HealthcareExpert Review of Precision Medicine and Drug Development · 2024
- Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinomaExpert Review of Precision Medicine and Drug Development · 2024
- Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligenceExpert Review of Precision Medicine and Drug Development · 2024
- Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiationExpert Review of Precision Medicine and Drug Development · 2023
- Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approachesExpert Review of Precision Medicine and Drug Development · 2023
- Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?Expert Review of Precision Medicine and Drug Development · 2022
- Accelerating precision ophthalmology: recent advancesExpert Review of Precision Medicine and Drug Development · 2022
- Personalizing treatments for patients based on cardiovascular phenotypingExpert Review of Precision Medicine and Drug Development · 2022
- Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancerExpert Review of Precision Medicine and Drug Development · 2022
- Challenges in biomarker-based clinical trials for patients with gastrointestinal malignanciesExpert Review of Precision Medicine and Drug Development · 2022
- Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?Expert Review of Precision Medicine and Drug Development · 2022
- Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directionsExpert Review of Precision Medicine and Drug Development · 2022
- Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug developmentExpert Review of Precision Medicine and Drug Development · 2022
- Personalised pharmacotherapy options for soft tissue sarcomasExpert Review of Precision Medicine and Drug Development · 2022
- Therapeutic potential of GABAA receptor subunit expression abnormalities in fragile X syndromeExpert Review of Precision Medicine and Drug Development · 2022
- Dopaminergic and other genes related to reward induced overeating, Bulimia, Anorexia Nervosa, and Binge eatingExpert Review of Precision Medicine and Drug Development · 2021
- Capabilities of neural network technologies for extracting new medical knowledge and enhancing precise decision making for patientsExpert Review of Precision Medicine and Drug Development · 2021
- Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimenExpert Review of Precision Medicine and Drug Development · 2021
- Prediction, diagnosis, prevention and treatment: genetic-led care of patients with diabetesExpert Review of Precision Medicine and Drug Development · 2021
- Targeted immunotherapies to consider for B Cell non-hodgkin lymphomaExpert Review of Precision Medicine and Drug Development · 2021
- Recent advances in precision medicine for the treatment of medullary thyroid cancerExpert Review of Precision Medicine and Drug Development · 2021
- Individualized management of cytomegalovirus in solid organ transplant recipientsExpert Review of Precision Medicine and Drug Development · 2021
- Brigatinib as a treatment of ALK-positive non-small cell lung cancerExpert Review of Precision Medicine and Drug Development · 2021
- Novel insights into the pathogenesis and treatment of NRAS mutant melanomaExpert Review of Precision Medicine and Drug Development · 2021
- An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromasExpert Review of Precision Medicine and Drug Development · 2021
- The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a reviewExpert Review of Precision Medicine and Drug Development · 2021
- Value of digital biomarkers in precision medicine: implications in cancer, autoimmune diseases, and COVID-19Expert Review of Precision Medicine and Drug Development · 2021
- The changing role of the pathologist in the era of targeted therapy in personalized medicineExpert Review of Precision Medicine and Drug Development · 2021
- Precision medicine for the treatment of triple negative breast cancer: opportunities and challengesExpert Review of Precision Medicine and Drug Development · 2021
- Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncologyExpert Review of Precision Medicine and Drug Development · 2021
- Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?Expert Review of Precision Medicine and Drug Development · 2021
- Slotting metabolomics into routine precision medicineExpert Review of Precision Medicine and Drug Development · 2021
- Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancerExpert Review of Precision Medicine and Drug Development · 2021
- Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatmentExpert Review of Precision Medicine and Drug Development · 2021
- Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemiaExpert Review of Precision Medicine and Drug Development · 2021
- Is there a worthwhile value in personalizing radiation therapy for breast cancer patients? Time for a new paradigm in the older adult populationExpert Review of Precision Medicine and Drug Development · 2021
- Mutation-dependent treatment approaches for patients with complex multiple myelomaExpert Review of Precision Medicine and Drug Development · 2021
- GUCY2C as a biomarker to target precision therapies for patients with colorectal cancerExpert Review of Precision Medicine and Drug Development · 2021
- The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasisExpert Review of Precision Medicine and Drug Development · 2021
- Math, magnets, and medicine: enabling personalized oncologyExpert Review of Precision Medicine and Drug Development · 2021
- Global personalization of antibiotic therapy in critically ill patientsExpert Review of Precision Medicine and Drug Development · 2021
- Genetic analysis of primary renal cell carcinoma to determine treatment approachesExpert Review of Precision Medicine and Drug Development · 2021
- Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiencyExpert Review of Precision Medicine and Drug Development · 2020
- Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancerExpert Review of Precision Medicine and Drug Development · 2020
- Durvalumab for the treatment of PD-L1 non-small cell lung cancerExpert Review of Precision Medicine and Drug Development · 2020